Blueprint Medicines (NASDAQ: BPMC) reported Q2 EPS of ($2.19), $0.36 better than the analyst estimate of ($2.55). Revenue for the quarter came in at $57.57 million versus the consensus estimate of $45.08 million.

For earnings history and earnings-related data on Blueprint Medicines (BPMC) click here.